CCCC (STOCKS)
C4 Therapeutics, Inc.
$4.080000
+0.180000 (+4.62%)
Prev close: $3.900000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Andrew J. Hirsch
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $558.62M
- Employees
- 110
- P/E (TTM)
- -4.08
- P/B (TTM)
- 1.94
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
4
Strong Buy
8
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.20 | $-0.38 | +0.1794 | +47.29% |
|
Dec 2025 (Q4)
|
$-0.18 | $-0.31 | +0.1298 | +41.90% |
|
Sep 2025 (Q3)
|
$-0.44 | $-0.41 | -0.0257 | -6.20% |
|
Jun 2025 (Q2)
|
$-0.37 | $-0.39 | +0.0217 | +5.54% |
Financial Statements
| Revenues | $35.04M |
| Benefits Costs and Expenses | $136.33M |
| Costs And Expenses | $136.33M |
| Nonoperating Income/Loss | $10.47M |
| Operating Expenses | $146.80M |
| Research and Development | $100.05M |
| Other Operating Expenses | $44.80M |
| Operating Income/Loss | -$111.77M |
| Income/Loss From Continuing Operations After Tax | -$101.42M |
| Income/Loss From Continuing Operations Before Tax | -$101.30M |
| Income Tax Expense/Benefit | $121.00K |
| Net Income/Loss | -$101.42M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$101.42M |
| Net Income/Loss Available To Common Stockholders, Basic | -$101.42M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.91 |
| Diluted Earnings Per Share | -$0.91 |
| Basic Average Shares | 212,382,483 |
| Diluted Average Shares | 212,382,483 |
| Assets | $359.40M |
| Current Assets | $262.90M |
| Cash | $300.40M |
| Accounts Receivable | $1.33M |
| Noncurrent Assets | $96.50M |
| Fixed Assets | $4.15M |
| Other Non-current Assets | $92.35M |
| Liabilities | $112.14M |
| Current Liabilities | $48.25M |
| Accounts Payable | $1.12M |
| Other Current Liabilities | $47.13M |
| Noncurrent Liabilities | $63.89M |
| Equity | $247.27M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $247.27M |
| Liabilities And Equity | $359.40M |
| Net Cash Flow From Operating Activities | -$84.87M |
| Net Cash Flow From Operating Activities, Continuing | -$84.87M |
| Net Cash Flow From Investing Activities | -$75.31M |
| Net Cash Flow From Investing Activities, Continuing | -$75.31M |
| Net Cash Flow From Financing Activities | $160.63M |
| Net Cash Flow From Financing Activities, Continuing | $160.63M |
| Net Cash Flow | $453.00K |
| Net Cash Flow, Continuing | $453.00K |
| Comprehensive Income/Loss | -$101.88M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$101.88M |
| Other Comprehensive Income/Loss | -$137.63M |